Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo ® ] Obtained from a Manufacturing Process Preserving IgA/IgM Potential of Human Plasma.
Christian DuellbergAchim HannappelSteffen KistnerOliver ManegPublished in: Drugs in R&D (2023)
constitutes a new high quality IVIG preparation derived from a novel manufacturing process that takes advantage of the full therapeutic immunoglobulin potential of human plasma.
Keyphrases